Samjin Pharm (005500) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Samjin Pharm stock KRW 22,008, price KRW 20,450, upside +7.6%, quality 55 out of 100. Rating: fairly valued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 15,569 KRW – 24,700 KRW · fair‑value band 13,119 KRW – 32,230 KRW · the 20,450 KRW price screens below the 22,008 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Samjin Pharm in your weekly email
Every Wednesday you see whether Samjin Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms.
Show moreShow less
The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases.
It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes.
In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Stock analysis
Samjin Pharm (005500) currently trades at 20,450 KRW, while our model-based Fair Value estimate is 22,008 KRW, so the stock looks roughly fairly valued today (gap 7.1%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 34,456 KRW per share, and 13 of the 25 models we run sit above the 20,450 KRW price.
Bear case: the Dividend Discount group reads lowest at 8,618 KRW, and 12 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: 13,119 KRW (bear) to 32,230 KRW (bull), the price of 20,450 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Samjin Pharm reported revenue of 309B KRW in FY2025 versus 250B KRW in FY2021, a compound +5.4%/yr. Reported net income was 24.2B KRW in FY2025, compounding −4.0%/yr from FY2021.
Key figures
Market cap 251B KRW (≈ $185M) Micro · P/E ratio 11.9 · P/S ratio 0.92 · EPS (TTM) 1,730 KRW · Dividend yield 3.9% · Net margin 8.0% · Return on equity 8.6% · Return on assets (EBIT) 6.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 20% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 8%, 005500 screens cheaper than that median.
Fair Value models
Bear13,119 KRWFair Value 22,008 KRWBull32,230 KRW
Price 20,450 KRW · Upside +7.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (797.23 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.56/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Start year 2020 (pandemic). Over 10 years: +3.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.7%
Dividend (yield on the price)3.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2.7% vs −2.0%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+27.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +24.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score55 · Below median
Fair Value upside+7.6% · Above median
Profitability
Return on equity (12 months)8.6% · Above median
Return on assets5.1% · Above median
Net margin (12 months)8.0% · Above median
Operating margin (12 months)22.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)1.9% · Below median
Dividend yield (12 months)3.9% · Top 25%
Balance sheet
Debt / equity0.10× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)11.9× · Cheapest 25%
P/B0.86× · Cheapest 25%
P/S (12 months)0.92× · Cheapest 25%
Price / free cash flow (fiscal year)26.1× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Samjin Pharm Fair Value". https://www.fairvalue-calculator.com/stock/005500
Frequently asked questions
Is Samjin Pharm (005500) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 22,008 KRW versus a price of 20,450 KRW, about +8% upside (fairly valued).
What is the fair value of 005500?
Our model-based fair value for Samjin Pharm is 22,008 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 20,450 KRW.
What is the quality score of 005500?
Samjin Pharm has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Samjin Pharm (005500)?
Our model-based price target is the fair value of 22,008 KRW (as of Nov 8, 2026) from 25 valuation models. Cautious scenario 13,119 KRW, optimistic scenario 32,230 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Samjin Pharm stock forecast for 2026?
Our models put fair value at 22,008 KRW, about +8% upside versus a price of 20,450 KRW (fairly valued). Cautious scenario 13,119 KRW, optimistic scenario 32,230 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Samjin Pharm (005500)?
Samjin Pharm reported trailing-twelve-month revenue of about 274B KRW (latest available figure, as of Nov 8, 2026).
Does Samjin Pharm pay a dividend?
Samjin Pharm currently shows a dividend yield of 3.91% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Samjin Pharm (005500) and when is the ex-dividend date?
Samjin Pharm pays a dividend of 800.00 KRW per share a year, a dividend yield of 3.9%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 1996. The payout ratio is 46.3% of earnings. Free cash flow covers the dividend 0.95 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Samjin Pharm (005500)?
For today's price to be fair in a discounted-cash-flow model, Samjin Pharm would have to grow free cash flow by +27.3 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.6 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 005500 use?
Our models discount Samjin Pharm at 11.6 %: a base by market capitalisation (micro), damped by beta 0.22, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Samjin Pharm that is +27.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Samjin Pharm (005500) delivered so far?
Over the past 5 years revenue at Samjin Pharm grew +5.6 % a year. The price currently implies free-cash-flow growth of +27.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Samjin Pharm (005500) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Samjin Pharm (+27.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Samjin Pharm (005500)?
The free-cash-flow yield on the price is 3.84 %: that much free cash flow Samjin Pharm produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Samjin Pharm (005500)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Samjin Pharm it is 22,008 KRW per share (as of Nov 8, 2026), against a price of 20,450 KRW. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Samjin Pharm stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 005500 trades below its calculated fair value: price 20,450 KRW, fair value 22,008 KRW, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 005500?
No. The price is what the market pays today (20,450 KRW); the fair value is what the company's own numbers justify (22,008 KRW). For Samjin Pharm the two are 1,558 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Samjin Pharm worth?
The market values Samjin Pharm at about 251B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 20,450 KRW; our models calculate a fair value of 22,008 KRW per share.
What do the bullish and bearish scenarios say about 005500?
Our models span a range for Samjin Pharm: cautious scenario 13,119 KRW, base 22,008 KRW, optimistic 32,230 KRW per share (as of Nov 8, 2026, price 20,450 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 005500?
Samjin Pharm trades at a price-to-earnings ratio of 11.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 22,008 KRW is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 13.3. Other multiples: P/B 0.9, P/S 0.9, EV/EBITDA 8.1.
How solid is the balance sheet of Samjin Pharm (005500)?
Balance-sheet figures for Samjin Pharm (as of Nov 8, 2026): return on equity 8.6%, debt of 0.10 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 005500 from its 52-week high?
Samjin Pharm trades at 20,450 KRW, about 17% below its 52-week high of 24,700 KRW and 20% above the low of 17,010 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 22,008 KRW is for.
Which stocks are comparable to Samjin Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Samjin Pharm stock attractive at the current price?
The data as of Nov 8, 2026: price 20,450 KRW, calculated fair value 22,008 KRW (+8%), Quality Score 55/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 005500 calculated?
We run Samjin Pharm through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 22,008 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Samjin Pharm currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Samjin Pharm (005500)?
The closing price on Nov 6, 2026 was 20,450 KRW. Our model-based fair value is 22,008 KRW, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Samjin Pharm right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (13,119 KRW to 32,230 KRW) leaves room in how you read the outcome.
Key figures of Samjin Pharm
How large is the market capitalisation of Samjin Pharm (005500)?
The market capitalisation of Samjin Pharm is 251B KRW (≈ $185M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Samjin Pharm (005500)?
The price-to-sales ratio of Samjin Pharm is 0.92 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Samjin Pharm (005500)?
Earnings per share at Samjin Pharm are 1,730 KRW (price ÷ EPS = P/E 11.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Samjin Pharm (005500)?
The dividend yield of Samjin Pharm is 3.9% (payout 46.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Samjin Pharm (005500)?
The net margin of Samjin Pharm is 8.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Samjin Pharm (005500)?
The return on equity (ROE) of Samjin Pharm is 8.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Samjin Pharm (005500)?
On an EBIT basis the return on assets of Samjin Pharm is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Samjin Pharm (005500)?
The operating margin of Samjin Pharm is 22.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Samjin Pharm (005500)?
Revenue at Samjin Pharm is growing +1.9% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Samjin Pharm (005500)?
Earnings per share at Samjin Pharm are growing +9.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Samjin Pharm (005500) carry?
The net debt of Samjin Pharm is 122B KRW (fiscal year 2025, ≈ 12.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Samjin Pharm in the live analysis
One click puts Samjin Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026